In This Story NVO LLY CI UNH CVS Novo Nordisk ( NVO ) CEO Lars Fruergaard Jørgensen agreed today, during a Senate committee hearing, to sit down with lawmakers and pharmacy benefit managers (PBMs) to look into the possibility of cutting list prices for the company’s popular diabetes and weight-loss drugs. Suggested Reading Starbucks' new CEO doesn't want the shake-up to end with him The Fed has moved on from inflation. People are still worried The biggest cement producers in the world have a

Tag-uri: Inflatie